Intestinal Mucosa-Associated Microflora in Ulcerative Colitis Patients Before and After Restorative Proctocolectomy with an Ileoanal Pouch

Almeida, Maristela Gomes de; Kiss, Desidério Roberto; Zilberstein, Bruno; Quintanilha, Alina Guimarães; Teixeira, Magaly G.; Habr‐Gama, Angelita

doi:10.1007/s10350-008-9347-8

Cited by 17 publications

(27 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The microbiota close to the mucosa, which differs from the luminal microbiota, has so far received less attention, and yet the mucosa-associated microbiota is very close to the inflammatory process. As inflammatory bowel disease (IBD) is a disorder of mucosal inflammation, the mucosa-associated microflora seems to be of great relevance to the disease process (1,20). Differences have been observed between the dominant fecal microbiota and the mucosa-associated microbiota at different sites of the colon and rectum in IBD versus healthy subjects (7).…”

mentioning

confidence: 99%

Real-Time Analysis of Mucosal Flora in Patients with Inflammatory Bowel Disease in India

et al. 2010

View full text Add to dashboard Cite

Mucosa-associated bacterial flora from control individuals and inflammatory bowel disease (IBD) patients were evaluated by real-time analysis using 16S rRNA-based genus-specific primers. Our data show a clear delineation in concentration of bacteria between the predominating and subdominating genera under disease conditions, indicating that the subsets of bacteria participating in the pathogenesis of ulcerative colitis (UC) and Crohn's disease (CD) are likely to be different.

show abstract

mentioning

confidence: 99%

Real-Time Analysis of Mucosal Flora in Patients with Inflammatory Bowel Disease in India

et al. 2010

View full text Add to dashboard Cite

show abstract

“…patients were free to leave the study at any time (withdrawal of consent). other reasons for withdrawal from the investigation were: lack of adherence to the therapeutic schedule or programmed controls (< 85%, poor compliance); onset of symptoms of relapse, confirmed by instrumental procedures (therapeutic failure); onset of drug-related adverse events requiring 1.5±0.6 1.3±0.5 ns t 3 1.4±0.6 1.2±0.4 ns t 4 1.5±0.6 1.2±0.4 P = 0.0040 interruption of treatment. The study was approved by the local ethics committee and all participants subscribed to an informed consent.…”

Section: Methodsmentioning

confidence: 99%

“…Whether these abnormalities are the cause or the result of the intense systemic inflammatory response in Uc is still unresolved. However, it is well documented that bacterial microflora is altered in patients with active disease 4 . recent studies reported a great variation in the effects of microbiota, focusing, in particular, on the effects of a pro-inflammatory enterotype on mucosal layer and disease activity 5 .…”

Section: Introductionmentioning

confidence: 99%

The long-term effects of probiotics in the therapy of ulcerative colitis: A clinical study

Palumbo¹,

Romeo²,

Gammazza³

et al. 2016

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

100

View full text Add to dashboard Cite

Aim.Intestinal dysbiosis seems to be the leading cause of inflammatory bowel diseases, and probiotics seems to represent the proper support against their occurrence. Actually, probiotic blends and anti-inflammatory drugs represent a weapon against inflammatory bowel diseases. The present study evaluates the long-term (2 years) effects of combination therapy (mesalazine plus a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4) on ulcerative colitis activity. Method. Sixty patients with moderate-to-severe ulcerative colitis were enrolled: 30 of them were treated with a single daily oral administration of mesalazine 1200 mg; 30 patients received a single daily oral administration of mesalazine 1200 mg and a double daily administration of a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4. The treatment was carried out for two years and the clinical response evaluated according to the Modified Mayo Disease Activity Index. Results. All patients treated with combination therapy showed better improvement compared to the controls. In particular, the beneficial effects of probiotics were evident even after two years of treatment. Conclusions. A long-term treatment modality of anti-inflammatory drugs and probiotics is viable and could be an alternative to corticosteroids in mild-to moderate ulcerative colitis.

show abstract

“…[9][10][11] Finally, the ileal mucosa can potentially be changed by the altered physiology ensuing from its new function as a fecal reservoir. 12,13 CD10 is a membrane-associated neutral peptidase, also known as neprilysin, enkephalinase, common acute lymphoblastic leukemia antigen, and neutral endopeptidase. 14 Previous studies have demonstrated its presence on the brush border of small intestinal mucosa and it has been studied and utilized in the diagnosis of microvillous inclusion disease.…”

mentioning

confidence: 99%

CD10 immunohistochemistry stains enteric mucosa, but negative staining is unreliable in the setting of active enteritis

Lloyd

Owens

2011

Modern Pathology

View full text Add to dashboard Cite

Ileal pouch-anal anastomosis is the definitive therapy for ulcerative colitis that is refractory to medical treatment or that has developed neoplasia. Patients with this procedure are routinely followed using directed endoscopic biopsies to monitor for dysplasia in the rectal cuff, residual/recurrent ulcerative colitis, and nonspecific acute inflammation of the ileal pouch (pouchitis), which have different clinical management and outcomes. Thus, accurate localization of mucosal biopsies is crucial to a definitive histological diagnosis, but is complicated by overlapping clinical presentations of pouchitis and ulcerative colitis, post-surgical and inflammatory changes to the mucosa, and altered endoscopic anatomy, resulting in difficulty determining whether a mucosal biopsy is ileal or rectal in origin for both the endoscopist and the pathologist. We explored the utility of CD10 immunohistochemistry to aid diagnosis in this clinical setting by highlighting the enteric mucosa, based on previous studies showing its utility in brush border staining and in the diagnosis of microvillous inclusion disease. We found uniformly positive CD10 immunostaining in normal enteric mucosa, but variable loss of expression in the setting of active enteritis. Specifically, CD10 staining was lost in up to 10% of the mucosa in 1/12 ileostomies and 4/13 enteric anastomoses, in 10-80% of the mucosa in 9/10 cases of Crohn's ileitis, in 10-60% of the mucosa in 7/16 ileal pouches, and in 20-90% of the mucosa in 6/8 cases of backwash ileitis, usually in the presence of active inflammation. There was no CD10 expression by normal or diseased colonic mucosa. Therefore, while CD10 immunostaining identifies normal enteric mucosa with 100% specificity, negative staining does not definitively exclude small intestinal mucosa in the setting of active enteritis, a common condition in ileal pouch mucosa.

show abstract

Intestinal Mucosa-Associated Microflora in Ulcerative Colitis Patients Before and After Restorative Proctocolectomy with an Ileoanal Pouch

Cited by 17 publications

References 16 publications

Real-Time Analysis of Mucosal Flora in Patients with Inflammatory Bowel Disease in India

Real-Time Analysis of Mucosal Flora in Patients with Inflammatory Bowel Disease in India

The long-term effects of probiotics in the therapy of ulcerative colitis: A clinical study

CD10 immunohistochemistry stains enteric mucosa, but negative staining is unreliable in the setting of active enteritis

Contact Info

Product

Resources

About